Published in J Virol on June 01, 2005
Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol (2009) 3.09
Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol (2009) 2.31
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest (2008) 1.74
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine (2006) 1.71
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine (2006) 1.43
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One (2015) 1.40
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine (2009) 1.36
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol (2007) 1.28
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21
A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS One (2010) 1.11
Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One (2010) 1.10
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology (2007) 1.09
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Evaluation of monkeypox disease progression by molecular imaging. J Infect Dis (2011) 1.07
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis (2012) 1.06
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine (2009) 1.06
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol (2007) 1.02
A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. Future Virol (2013) 1.01
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. Vaccine (2011) 0.96
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine (2009) 0.94
Expansion, reexpansion, and recall-like expansion of Vgamma2Vdelta2 T cells in smallpox vaccination and monkeypox virus infection. J Virol (2009) 0.93
Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox. Virology (2011) 0.90
A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vaccin Immunother (2012) 0.90
Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol (2008) 0.88
Comparative pathology of smallpox and monkeypox in man and macaques. J Comp Pathol (2012) 0.87
Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol (2013) 0.87
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox. Antiviral Res (2012) 0.85
Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J Virol (2011) 0.85
Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni). Virology (2014) 0.85
Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs. Vaccine (2011) 0.84
Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol (2008) 0.84
Development of ST-246® for Treatment of Poxvirus Infections. Viruses (2010) 0.84
Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol (2011) 0.82
Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. J Virol (2011) 0.81
Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. Clin Vaccine Immunol (2007) 0.79
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One (2012) 0.79
Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques. Vaccine (2011) 0.79
Application of the Ibis-T5000 pan-Orthopoxvirus assay to quantitatively detect monkeypox viral loads in clinical specimens from macaques experimentally infected with aerosolized monkeypox virus. Am J Trop Med Hyg (2010) 0.78
Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates. PLoS One (2013) 0.78
Systemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8⁺ T cells. J Virol (2013) 0.78
Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain. PLoS One (2013) 0.77
L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines. J Transl Med (2013) 0.77
Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines. PLoS One (2016) 0.75
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects. PLoS One (2016) 0.75
Characterizing monkeypox virus specific CD8+ T cell epitopes in rhesus macaques. Virology (2013) 0.75
Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. Clin Vaccine Immunol (2016) 0.75
Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS One (2015) 0.75
Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus. J Virol (2015) 0.75
Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. PLoS Pathog (2015) 0.75
Defending against smallpox: a focus on vaccines. Expert Rev Vaccines (2016) 0.75
Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines. Vaccine (2010) 0.75
Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection. PLoS One (2014) 0.75
Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease. Virology (2015) 0.75
Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications. Vaccines (Basel) (2014) 0.75
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92
[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50
The confirmation and maintenance of smallpox eradication. N Engl J Med (1980) 2.46
The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2001) 2.38
Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract (2002) 2.36
Clinical virology in real time. J Clin Virol (2002) 2.16
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
US military smallpox vaccination program experience. JAMA (2003) 2.03
Progressive vaccinia. Clin Infect Dis (2003) 2.02
Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol (2002) 1.86
Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol (2002) 1.62
Zoonotic poxvirus infections in humans. Curr Opin Infect Dis (2004) 1.58
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA (1970) 1.35
Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis (2003) 1.03
Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice. J Immunol (2004) 0.89
Development of vaccines for bio-warfare agents. Dev Biol (Basel) (2002) 0.85
Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome. Clin Infect Dis (2003) 0.84
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med (2012) 22.75
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Mapping the antigenic and genetic evolution of influenza virus. Science (2004) 14.28
Global patterns of influenza a virus in wild birds. Science (2006) 13.80
Airborne transmission of influenza A/H5N1 virus between ferrets. Science (2012) 13.48
Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A (2004) 12.39
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol (2005) 10.77
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio (2012) 8.54
Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science (2009) 7.80
Aetiology: Koch's postulates fulfilled for SARS virus. Nature (2003) 7.51
The severe acute respiratory syndrome. N Engl J Med (2003) 7.48
Diversity of microRNAs in human and chimpanzee brain. Nat Genet (2006) 6.57
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature (2013) 6.39
H5N1 Virus Attachment to Lower Respiratory Tract. Science (2006) 6.34
Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis (2004) 6.16
Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds. PLoS Pathog (2007) 6.04
Human bocavirus and acute wheezing in children. Clin Infect Dis (2007) 5.88
A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A (2004) 5.76
Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis (2002) 5.64
Avian H5N1 influenza in cats. Science (2004) 5.40
Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol (2007) 4.86
Analysis of the genomic sequence of a human metapneumovirus. Virology (2002) 4.64
Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med (2008) 3.97
Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio (2012) 3.96
Virology: SARS virus infection of cats and ferrets. Nature (2003) 3.86
Metapneumovirus and acute wheezing in children. Lancet (2002) 3.64
Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 3.61
The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science (2012) 3.50
Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science (2013) 3.38
Wild ducks as long-distance vectors of highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis (2008) 3.37
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis (2004) 2.96
Great ape genetic diversity and population history. Nature (2013) 2.95
Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis (2003) 2.91
Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe. Emerg Infect Dis (2005) 2.90
Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol (2004) 2.88
Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis (2010) 2.81
Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol (2006) 2.77
Surveillance of influenza A virus in migratory waterfowl in northern Europe. Emerg Infect Dis (2007) 2.76
Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine (2013) 2.69
Effects of influenza A virus infection on migrating mallard ducks. Proc Biol Sci (2009) 2.69
Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis (2004) 2.68
The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. J Infect Dis (2007) 2.58
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One (2009) 2.49
Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res (2004) 2.43
A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS (2005) 2.34
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med (2004) 2.31
Pause on avian flu transmission research. Science (2012) 2.24
In vitro assessment of attachment pattern and replication efficiency of H5N1 influenza A viruses with altered receptor specificity. J Virol (2010) 2.23
Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One (2008) 2.20
Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis (2013) 2.19
Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission. J Virol (2010) 2.19
Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol (2010) 2.17
Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature (2013) 2.17
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med (2009) 2.12
Upsurge of human enterovirus 68 infections in patients with severe respiratory tract infections. J Clin Virol (2011) 2.10
Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog (2007) 2.09
Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis (2009) 2.07
Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A. Proc Natl Acad Sci U S A (2003) 2.03
Molecular determinants of adaptation of highly pathogenic avian influenza H7N7 viruses to efficient replication in the human host. J Virol (2009) 1.99
Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med (2013) 1.95
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine (2005) 1.94
Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol (2006) 1.90
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A (2004) 1.89
Rat-to-human transmission of Cowpox infection. Emerg Infect Dis (2002) 1.87
Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol (2004) 1.87
Human picobirnaviruses identified by molecular screening of diarrhea samples. J Clin Microbiol (2010) 1.86
Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests. J Clin Microbiol (2008) 1.85
Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med (2003) 1.81